Kerala SMA Drug Scheme: Risdiplam Procurement for UPSC

Kerala SMA drug scheme

The Kerala SMA drug scheme is in focus after the state ordered 2,159 bottles of Risdiplam. The procurement also connects with wider questions about healthcare and drug regulation.

Quick answer: On 29 October 2026, Kerala announced procurement orders for 2,159 bottles of Risdiplam for spinal muscular atrophy (SMA). The Kerala SMA drug scheme, called Kerala United Against Rare Diseases (KARE), aims to maintain treatment access. Moreover, a lower-cost generic supplied since 19 October has reduced the medicine’s cost.

Important for

Prelims

Rare diseases, SMA and generic medicines

Mains

GS Paper II: Health

Procurement order

2,159 bottles

Generic price

Around ₹11,000 per bottle

Treatment clinic

SAT Hospital, Thiruvananthapuram

What is the Kerala SMA drug scheme?

KARE is Kerala’s scheme for providing treatment and medicines to children affected by SMA. SMA is a rare, life-threatening genetic disorder that progressively weakens muscles. Consequently, it can severely impair movement and breathing.

Kerala provides Risdiplam through its SMA clinic at SAT Hospital in Thiruvananthapuram. Risdiplam is the first oral SMA treatment that can be taken at home. However, the procurement order itself does not establish that all bottles have been delivered.

Why is Risdiplam procurement in the news?

Health Minister K. Muraleedharan announced the 2,159-bottle order in the Kerala Assembly. He was responding to a submission by P.K. Firos, a Member of the Legislative Assembly. The order aims to maintain medicine availability and prevent treatment disruption.

Since 19 October, Kerala has supplied Natsmart, a domestic generic version manufactured by Natco Pharma. Moreover, its price is around ₹11,000 per bottle, compared with the earlier negotiated price of ₹5.5 lakh per bottle.

Key features and treatment support

The scheme combines free medicine for eligible children with clinical and rehabilitation support.

Feature	Details
Free medicine	Risdiplam for children under 12 since 2022
Long-term access	Steps taken to provide medicine lifelong to all eligible persons
Other care	Physiotherapy, respiratory therapy and devices, rehabilitation and surgery
Proposed support	Possible treatment, financial and psychological programmes with the Kerala Social Security Mission

What are the implementation challenges?

The Kerala SMA drug scheme must ensure continuity as well as affordability.

Continuous supply: Procurement orders must translate into reliable availability; otherwise, treatment may be interrupted.
Comprehensive care: Medicine alone does not cover all support needs; therefore, respiratory care and rehabilitation remain important.
Family burden: Treatment costs can strain households; in addition, families may need psychological support.

What is the way forward?

Reliable procurement and coordinated clinical care can support uninterrupted treatment. In addition, the proposed collaboration with the Kerala Social Security Mission could complement medicine access with family support.

Source: The Hindu, 29 October 2026

Earlier on CBL

Healthcare Regulation: UPSC Analysis of Drug & Hospital Laws (11 Aug 2026)
Biosimilar Standards: India’s Biopharma Quality Push (18 Sep 2026)

Punjab & Haryana PCS Angle

Punjab PCS and Haryana HCS may test rare diseases, generic medicines and state-led healthcare initiatives in General Studies. In addition, compare how procurement and treatment delivery affect access to public healthcare.

Prelims Practice Corner

Q1. Consider the following statements about spinal muscular atrophy:
1. It is a genetic disorder.
2. It progressively weakens muscles and can impair breathing.
Which of the statements given above is/are correct?

(a) 1 only
(b) 2 only
(c) Both 1 and 2
(d) Neither 1 nor 2

Show answer

Answer: (c). Both are correct because SMA is genetic and affects muscle strength, movement and breathing.

Q2. With reference to Risdiplam in Kerala, consider the following statements:
1. It is an oral treatment that can be taken at home.
2. The state has ordered 2,159 bottles to support continued availability.
Which of the statements given above is/are correct?

(a) 1 only
(b) 2 only
(c) Both 1 and 2
(d) Neither 1 nor 2

Show answer

Answer: (c). Both are correct because Risdiplam is oral and Kerala has issued the stated procurement order.

Mains Practice Questions

Q1. Discuss how state procurement and comprehensive care can improve access to treatment for rare diseases. (10 marks, GS Paper II)

Answer Structure

Intro: Introduce SMA and Kerala’s procurement initiative.

Body: Discuss generic pricing, supply continuity, clinical care and family support.

Conclusion: Emphasise coordinated and uninterrupted treatment.

Frequently Asked Questions

What is spinal muscular atrophy?

SMA is a rare genetic disorder that progressively weakens muscles. As a result, it can severely affect movement and breathing.

How many bottles of Risdiplam has Kerala ordered?

Kerala has issued orders for 2,159 bottles. The order aims to ensure continued availability of the medicine.

What is Natsmart and how much does it cost?

Natsmart is a generic version of Risdiplam costing around ₹11,000 per bottle. Kerala has supplied it since 19 October 2026, and Natco Pharma manufactures it in India.

Who receives free Risdiplam under KARE?

Kerala has provided it free to children under 12 since 2022. In addition, the state has taken steps to provide it lifelong to all eligible persons.

Related Current Affairs

Preparing for UPSC, PCS or HCS?

Talk to a mentor at Chetan Bharat Learning, Chandigarh. Free guidance on choosing the right exam and building a study plan.

Chat on WhatsApp Call 97793 53345

UPSC / IAS / PCS coaching in Chandigarh · Trusted by aspirants across Punjab & Haryana